NO973715D0 - Transdermal formulering - Google Patents

Transdermal formulering

Info

Publication number
NO973715D0
NO973715D0 NO973715A NO973715A NO973715D0 NO 973715 D0 NO973715 D0 NO 973715D0 NO 973715 A NO973715 A NO 973715A NO 973715 A NO973715 A NO 973715A NO 973715 D0 NO973715 D0 NO 973715D0
Authority
NO
Norway
Prior art keywords
transdermal formulation
transdermal
formulation
Prior art date
Application number
NO973715A
Other languages
English (en)
Norwegian (no)
Other versions
NO973715L (no
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Lisa Ann Shipley
Kirti H Valia
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO973715D0 publication Critical patent/NO973715D0/no
Publication of NO973715L publication Critical patent/NO973715L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/02—Adhesive bandages or dressings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO973715A 1995-02-17 1997-08-12 Transdermal formulering NO973715L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39044595A 1995-02-17 1995-02-17
US48101695A 1995-06-07 1995-06-07
PCT/US1996/001371 WO1996025154A1 (en) 1995-02-17 1996-02-01 Transdermal formulation

Publications (2)

Publication Number Publication Date
NO973715D0 true NO973715D0 (no) 1997-08-12
NO973715L NO973715L (no) 1997-08-12

Family

ID=27013141

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973715A NO973715L (no) 1995-02-17 1997-08-12 Transdermal formulering

Country Status (22)

Country Link
US (1) US5858393A (ja)
EP (1) EP0727208B1 (ja)
JP (1) JPH11505513A (ja)
KR (1) KR19980702239A (ja)
CN (1) CN1181007A (ja)
AR (1) AR002027A1 (ja)
AU (1) AU700023B2 (ja)
BR (1) BR9607722A (ja)
CA (1) CA2212874A1 (ja)
CO (1) CO4700408A1 (ja)
CZ (1) CZ255097A3 (ja)
DE (1) DE69614419T2 (ja)
ES (1) ES2159683T3 (ja)
FI (1) FI973362A (ja)
HU (1) HUP9802070A3 (ja)
IL (1) IL116997A0 (ja)
NO (1) NO973715L (ja)
NZ (1) NZ302147A (ja)
PE (1) PE17897A1 (ja)
TR (1) TR199700799T1 (ja)
WO (1) WO1996025154A1 (ja)
YU (1) YU6196A (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6417227B1 (en) 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
WO2001030316A2 (en) * 1999-10-28 2001-05-03 3M Innovative Properties Company Transdermal drug delivery devices comprising (r)-(z)-1-azabicyclo(2.2.1)heptan-3-one, 0-(3(3-methoxyphenyl)-2-propynyl)oxime
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US20090287180A1 (en) * 2008-05-19 2009-11-19 Diperna Paul M Disposable pump reservoir and related methods
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) * 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
WO2011014704A2 (en) * 2009-07-30 2011-02-03 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
IT1233860B (it) * 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
DK198590D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
PT714394E (pt) * 1993-08-19 2001-12-28 Novo Nordisk As Metodo antipsicotico com derivados de tiadiazol e oxadiazol

Also Published As

Publication number Publication date
AR002027A1 (es) 1998-01-07
FI973362A0 (fi) 1997-08-15
HUP9802070A2 (hu) 1999-02-01
FI973362A (fi) 1997-08-15
CO4700408A1 (es) 1998-12-29
CZ255097A3 (en) 1997-12-17
WO1996025154A1 (en) 1996-08-22
DE69614419T2 (de) 2002-05-23
CN1181007A (zh) 1998-05-06
KR19980702239A (ko) 1998-07-15
NZ302147A (en) 1998-10-28
YU6196A (sh) 1998-09-18
BR9607722A (pt) 1998-07-14
TR199700799T1 (xx) 1998-02-21
MX9706143A (es) 1997-11-29
IL116997A0 (en) 1996-06-18
ES2159683T3 (es) 2001-10-16
US5858393A (en) 1999-01-12
AU4774296A (en) 1996-09-04
EP0727208A1 (en) 1996-08-21
DE69614419D1 (de) 2001-09-20
JPH11505513A (ja) 1999-05-21
NO973715L (no) 1997-08-12
PE17897A1 (es) 1997-06-12
AU700023B2 (en) 1998-12-17
EP0727208B1 (en) 2001-08-16
HUP9802070A3 (en) 2000-09-28
CA2212874A1 (en) 1996-08-22

Similar Documents

Publication Publication Date Title
DE69634256D1 (de) Zementformulierung
DE69627539D1 (de) Verpackungsfreie bioelektrode
DK1093815T3 (da) Oral 2-methyl-thieno-benzodiazepinformulering
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
NO962381L (no) Spiss-beskytter-innretning
DE69621528D1 (de) Anti-inflamatorische agenzien
DE59602881D1 (de) Sollwertgeber
PT828506E (pt) Agentes endoparasiticidas
NO981008D0 (no) Farmasöytisk formulering
PT778023E (pt) Agentes neuroprotectores
NO973471D0 (no) Transdermal formulering
BR9607058A (pt) Composição
BR9606809A (pt) Composição inseticidamente ativa
ATA181095A (de) Probiotisch wirksame formulierung
FI973362A (fi) Transdermaalinen formula
PT728814E (pt) Composicao betuminosa
BR9609903A (pt) ComposiçÃo inseticidamente ativa
IL116999A0 (en) Transdermal formulation
DE69631378D1 (de) Pestizide formulierung
DE69616374D1 (de) Germizide zusammensetzung
DE69430362D1 (de) Ektoparasitizide formulierung
FI973230A0 (fi) Uusi farmaseuttinen formulaatio
BR9607946A (pt) Composição
FI954547A0 (fi) Asemointilaite
SE9500036D0 (sv) Formulation